Skip to content

LUMIGAN® (bimatoprost ophthalmic solution) 0.03%

LUMIGAN®, approved by the U.S. Food and Drug Administration (FDA) in 2001, is indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Based on its efficacy and safety profile demonstrated over five years, LUMIGAN® received a first-line indication from the FDA in 2006 and is now used as an initial treatment in an increasing number of patients. LUMIGAN® offers a once-a-day dosing regimen. Maintaining once-daily dosing can be convenient for patients.

Glaucoma is one of the leading causes of preventable blindness in the United States 1 and affects approximately 3 million people in the United States and an estimated 65 million people worldwide.2 Elevated IOP represents a major risk factor for vision loss associated with open-angle glaucoma; the higher the IOP, the greater the likelihood of optic nerve damage, which can lead to vision loss and potential blindness. LUMIGAN® delivers effective and sustained lowering of IOP,3,4 which is significant because elevated IOP is the only risk factor that can currently be treated. An estimated 3 to 6 million people in the United States have elevated IOP.5 Talk with your eye care professional about whether LUMIGAN® is right for you.

Important Safety Information

LUMIGAN® ophthalmic solution has been reported to cause darkening (pigmentation) of eye color, eyelid skin and eyelashes, as well as increased growth of eyelashes. Pigmentation changes can increase as long as LUMIGAN® is used. After stopping LUMIGAN®, darkening of eye color is likely to be permanent while darkening of the eyelid skin and eyelash changes may be reversible. The effects of increased darkening beyond five years are not known.

The most common side effects are eye redness, growth of eyelashes, and itchy eyes.

Please See Full LUMIGAN® Product Information (PDF) 
LUMIGAN® Fact Sheet (PDF) 
Allergan Glaucoma Portfolio Fact Sheet (PDF) 
LUMIGAN® Web site 



  1. American Glaucoma Society. Available at: http://www.glaucomaweb.org/displaycommon.cfm?an=10 . Accessed January 10, 2008
  2. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology, 2005; 112(5):863-868
  3. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Amer J Ophthalmol 2003; 135(1): 55-63
  4. Higginbotham EJ, Schuman JS, Goldberg I, et al., for the Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002; 120(10): 1286-1293
  5. Kass, Michael A., MD. The Ocular Hypertension Treatment Study. Arch Ophthalmol. 2002; 120:701-713